Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation

• Main Authors: Nattayaporn Apaijai, Dalila Monica Moisescu, Siripong Palee, Christian Mervyn McSweeney, Napatsorn Saiyasit, Chayodom Maneechote, Chiraphat Boonnag, Nipon Chattipakorn, Siriporn C. Chattipakorn
• 格式: 雜誌
• 出版: 2019
• 主題: Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85059900929&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/63721

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. Background Cardiac ischemic/reperfusion (I/R) injury leads to brain damage. A new antihyperlipidemic drug is aimed at inhibitingPCSK9 (proprotein convertase subtilisin/kexin type 9), a molecule first identifi...